Navigation Links
Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

DURHAM, N.C., Nov. 11, 2010 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos' Arcelis™ immunotherapy at the Lazard Capital Markets 7th Annual Healthcare Conference in New York at 11 a.m. EST on Wednesday, Nov. 17, 2010.  The conference will take place at The St. Regis New York.

Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS 003, in mid-2011.  The company recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS 003 in combination with sunitinib. Argos' Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option of HIV-1 infected patients.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy c
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
3. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
10. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
11. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Capital, a firm specializing in acquiring and managing food ... the Slim-Fast brand from Unilever. Unilever will retain a ... were not disclosed. Slim-Fast is a branded ... shakes, powders, bars and snacks to retail customers throughout ... United Kingdom and Ireland.  The ...
(Date:7/10/2014)... 15, 2014 -- According to the International Atomic ... security comes from terrorists acquiring sufficient quantities of ... a crude nuclear explosive device. The IAEA also ... have involved gram-level quantities, which can be challenging ... to a new study appearing this week in ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Neurognostics, Inc ., a Wisconsin company specializing in functional ... that the Food and Drug Administration (FDA) issued a ... MindState fDAD. MindState fDAD had previously received clearance ... The Special 510(k) allows Neurognostics to enhance fDAD by ...
... eMed , a Merge Healthcare company and a ... the release of Cedara I-ReadMammo digital mammography workstation ... product is designed to help organizations streamline breast ... mammography. , ,I-ReadMammo was designed to help ...
... a country that invented take out food, that is in love ... in motion, it was inevitable that work and indeed the workplace ... the place where knowledge work happens has shifted from primarily office ... a subway car, walking down the street or of course, hanging ...
Cached Biology Technology:Who moved the workplace? 2Who moved the workplace? 3Who moved the workplace? 4
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... July 10, 2014---A team of researchers from The Chinese ... identified a gene of wild soybean linked to salt ... grow in saline soil. This study published online in ... unveil novel genomic information for crop improvement. , Soybean ... domestication and human selection, cultivated soybeans have less genetic ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... COLD SPRING HARBOR, N.Y. (Thurs., Oct. 1, 2009) ... choice for understanding where and when genes are expressed in ... physiological or environmental conditions. Recent discoveries have revolutionized our ... active in a much wider set of biological processes than ...
... Spatial Integrated Systems, Inc. ("SIS"), a leader in ... digital 3D data capture and processing technologies, announced ... been published for "system and method for generating ... No. US2009/0169095A1. , "We are pleased that our ...
... BATON ROUGE For Sophie Warny, LSU assistant professor of ... Natural Science, years of patience in analyzing Antarctic samples with ... and colleagues from around the world now have proof of ... 15.7 million years ago and lasted for a few thousand ...
Cached Biology News:Cold Spring Harbor Protocols features RNA analysis methods 2Spatial Integrated Systems, Inc. Files Patent Application 2Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 2Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 3Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 4
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... Dermal Fibroblasts (Mouse/BalbC) and media. This cell ... and is guaranteed to provide an additional ... date supplied, when used with the recommended ... 18.5 ,Applications: ,Cultivation: Plate at ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... statistical software package for scientists and engineers ... without being a statistical expert.Just answer a ... and SigmaStat suggests the appropriate test. It ... assumptions and suggests another test if your ...
Biology Products: